Literature DB >> 24534469

Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas.

Mingzhou Guo1, Yan Jia, Zhengtao Yu, Michael G House, Manel Esteller, Malcolm V Brock, James G Herman.   

Abstract

Early detection and multi-modality curative treatment for pancreatic cancer remain unsatisfactory due to the insufficient understanding of the mechanisms underlying tumor progression. Epigenetic events, including aberrant methylation of tumor suppressor gene promoter regions, may contribute to tumorigenesis involving both the exocrine and endocrine pancreas. Methylation changes of specific gene promoter regions were examined in 48 resected neoplasms of the exocrine and endocrine pancreas, which were obtained as paraffin-embedded tissue samples. The pancreatic neoplasms included acinar cell carcinoma (n=12), adenocarcinoma (n=18), and islet cell tumors (n=18). DNA methylation was determined with a nested methylation-specific PCR (MSP) technique incorporating an initial bisulfite modification of tumor DNA for the promoter regions associated with 14 tumor suppressor genes. In decreasing order, the 6 most frequently methylated genes were: APC 50%, BRCA1 46%, p16INK4a 35%, p15INK4b 35%, RARβ 35%, and p73 33%. Overall, 94% of the tumors had methylation of at least one gene, and methylation of two or more genes was present in 69% of pancreatic tumors. Pancreatic adenocarcinomas had patterns of gene methylation that differed from pancreatic endocrine tumors. These differences were most notable for the APC and hMLH1 genes.

Entities:  

Mesh:

Year:  2014        PMID: 24534469      PMCID: PMC4061564     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  29 in total

1.  Tumor-suppressive pathways in pancreatic carcinoma.

Authors:  E Rozenblum; M Schutte; M Goggins; S A Hahn; S Panzer; M Zahurak; S N Goodman; T A Sohn; R H Hruban; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.

Authors:  M Esteller; M Sanchez-Cespedes; R Rosell; D Sidransky; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 3.  Progress in cancer genetics: lessons from pancreatic cancer.

Authors:  M Goggins; S E Kern; J A Offerhaus; R H Hruban
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

4.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

5.  An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12.

Authors:  M Schutte; E Rozenblum; C A Moskaluk; X Guan; A T Hoque; S A Hahn; L T da Costa; P J de Jong; S E Kern
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.

Authors:  C Caldas; S A Hahn; L T da Costa; M S Redston; M Schutte; A B Seymour; C L Weinstein; R H Hruban; C J Yeo; S E Kern
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

7.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

Authors:  N S Pellegata; F Sessa; B Renault; M Bonato; B E Leone; E Solcia; G N Ranzani
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

9.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis.

Authors:  S A Belinsky; K J Nikula; W A Palmisano; R Michels; G Saccomanno; E Gabrielson; S B Baylin; J G Herman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

Review 10.  Genetic abnormalities in pancreatic cancer.

Authors:  Patrick S Moore; Stefania Beghelli; Giuseppe Zamboni; Aldo Scarpa
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

View more
  17 in total

1.  Exome Sequencing of Pancreatic Acinar Carcinoma Identified Distinctive Mutation Patterns.

Authors:  Yuanhang Liu; Massimo Raimondo; Michael B Wallace; Kabir Mody; John A Stauffer; Lizhi Zhang; Baoan Ji; Yan Bi
Journal:  Pancreas       Date:  2021-08-01       Impact factor: 3.243

2.  APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors.

Authors:  Mireia M Ginesta; Zamira Vanessa Diaz-Riascos; Juli Busquets; Núria Pelaez; Teresa Serrano; Miquel Àngel Peinado; Rosa Jorba; Francisco Javier García-Borobia; Gabriel Capella; Joan Fabregat
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

3.  TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.

Authors:  A K Thakur; J Nigri; S Lac; J Leca; C Bressy; P Berthezene; L Bartholin; P Chan; E Calvo; J L Iovanna; S Vasseur; F Guillaumond; R Tomasini
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

4.  APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice.

Authors:  T-L Kuo; C-C Weng; K-K Kuo; C-Y Chen; D-C Wu; W-C Hung; K-H Cheng
Journal:  Oncogene       Date:  2015-09-28       Impact factor: 9.867

Review 5.  Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments.

Authors:  Javier Martinez-Useros; Mario Martin-Galan; Maria Florez-Cespedes; Jesus Garcia-Foncillas
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

6.  A seven-gene CpG-island methylation panel predicts breast cancer progression.

Authors:  Yan Li; Anatoliy A Melnikov; Victor Levenson; Emanuela Guerra; Pasquale Simeone; Saverio Alberti; Youping Deng
Journal:  BMC Cancer       Date:  2015-05-19       Impact factor: 4.430

Review 7.  The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.

Authors:  Dan Gao; James G Herman; Mingzhou Guo
Journal:  Oncotarget       Date:  2016-06-14

Review 8.  Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.

Authors:  Brittany R Silverman; Jiaqi Shi
Journal:  Int J Mol Sci       Date:  2016-12-19       Impact factor: 5.923

9.  Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis.

Authors:  Hironori Hayashi; Koji Amaya; Tomokazu Tokoro; Kosuke Mori; Shunsuke Takenaka; Yuya Sugimoto; Yuto Kitano; Toru Kurata; Shunsuke Kawai; Atsushi Hirose; Tomoya Tsukada; Masahide Kaji; Koichi Shimizu; Kiichi Maeda
Journal:  Mol Clin Oncol       Date:  2021-06-29

Review 10.  Surgical and molecular pathology of pancreatic neoplasms.

Authors:  Wenzel M Hackeng; Ralph H Hruban; G Johan A Offerhaus; Lodewijk A A Brosens
Journal:  Diagn Pathol       Date:  2016-06-07       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.